ZA9010452B - Pharmaceutical preparation for oral administration in fluid form - Google Patents

Pharmaceutical preparation for oral administration in fluid form

Info

Publication number
ZA9010452B
ZA9010452B ZA9010452A ZA9010452A ZA9010452B ZA 9010452 B ZA9010452 B ZA 9010452B ZA 9010452 A ZA9010452 A ZA 9010452A ZA 9010452 A ZA9010452 A ZA 9010452A ZA 9010452 B ZA9010452 B ZA 9010452B
Authority
ZA
South Africa
Prior art keywords
oral administration
pharmaceutical preparation
fluid form
psychotropic
granules
Prior art date
Application number
ZA9010452A
Other languages
English (en)
Inventor
Gerrit Bernardus Maria Beuving
Bernardus Maria Beuving Gerrit
Henrik De Nijs
De Nijs Henrik
Original Assignee
Akzo Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nv filed Critical Akzo Nv
Publication of ZA9010452B publication Critical patent/ZA9010452B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA9010452A 1989-12-30 1990-12-28 Pharmaceutical preparation for oral administration in fluid form ZA9010452B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL8903199 1989-12-30

Publications (1)

Publication Number Publication Date
ZA9010452B true ZA9010452B (en) 1991-10-30

Family

ID=19855853

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9010452A ZA9010452B (en) 1989-12-30 1990-12-28 Pharmaceutical preparation for oral administration in fluid form

Country Status (14)

Country Link
US (1) US5238688A (da)
EP (1) EP0436252B1 (da)
JP (1) JP3051459B2 (da)
KR (1) KR0156735B1 (da)
AT (1) ATE93136T1 (da)
AU (1) AU634614B2 (da)
CA (1) CA2033418C (da)
DE (1) DE69002822T2 (da)
DK (1) DK0436252T3 (da)
ES (1) ES2060001T3 (da)
IE (1) IE63986B1 (da)
NZ (1) NZ236626A (da)
PT (1) PT96401B (da)
ZA (1) ZA9010452B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328688A (en) * 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
DE69913116T2 (de) * 1998-04-02 2004-06-03 Akzo Nobel N.V. Orale flüssige lösung enthaltend das antidepressivum mirtazapine
US6492320B2 (en) * 1999-09-24 2002-12-10 Rohm And Hass Company Multifunctional, granulated pellet aid and process
TWI256309B (en) * 1999-10-13 2006-06-11 Akzo Nobel Nv New formulation of mirtazapine
AU780817B2 (en) * 2000-01-19 2005-04-21 Akzo Nobel N.V. Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
WO2003077842A2 (en) * 2002-03-12 2003-09-25 Bristol-Myers Squibb Company Palatable oral suspension and method
US7632521B2 (en) * 2003-07-15 2009-12-15 Eurand, Inc. Controlled release potassium chloride tablets
US7838029B1 (en) * 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
EP1689371A2 (en) * 2003-11-25 2006-08-16 Aurobindo Pharma Limited Pharmaceutical compositions of mirtazapine
DE102004034043A1 (de) * 2004-07-13 2006-02-09 Krka Tovarna Zdravil, D.D. Feste pharmazeutische Zusammensetzung, die Mirtazapin enthält
US7811604B1 (en) 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4128641A (en) * 1975-07-31 1978-12-05 Hzi Research Center Inc. Tetracyclic psychotropic drug
NL7809726A (nl) * 1978-09-26 1980-03-28 Akzo Nv Nieuwe tetracyclische verbindingen.
JPS5665825A (en) * 1979-10-31 1981-06-03 Mochida Pharmaceut Co Ltd Remedy for peptic ulcer
US4623588A (en) * 1984-02-06 1986-11-18 Biotek, Inc. Controlled release composite core coated microparticles
US4870060A (en) * 1985-03-15 1989-09-26 Janssen Pharmaceutica Derivatives of γ-cylodextrin
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
DE3775880D1 (da) * 1986-09-18 1992-02-20 London School Of Pharmacy Innovations Ltd., London, Gb
DE3856555T2 (de) * 1987-10-16 2004-04-29 Elan Corp. Plc Diltiazem-Zusammensetzungen mit kontrollierter Wirkstoffabsorption
EP0319061A1 (en) * 1987-11-28 1989-06-07 Akzo N.V. Medicament with antiemetic action

Also Published As

Publication number Publication date
CA2033418C (en) 2002-05-14
NZ236626A (en) 1992-10-28
EP0436252B1 (en) 1993-08-18
CA2033418A1 (en) 1991-07-01
JP3051459B2 (ja) 2000-06-12
DE69002822T2 (de) 1993-12-23
DE69002822D1 (de) 1993-09-23
PT96401A (pt) 1991-10-15
KR0156735B1 (ko) 1998-11-16
DK0436252T3 (da) 1993-12-27
US5238688A (en) 1993-08-24
EP0436252A1 (en) 1991-07-10
IE904531A1 (en) 1991-07-03
PT96401B (pt) 1998-06-30
AU6839890A (en) 1991-07-04
JPH04210638A (ja) 1992-07-31
AU634614B2 (en) 1993-02-25
ATE93136T1 (de) 1993-09-15
KR910011266A (ko) 1991-08-07
ES2060001T3 (es) 1994-11-16
IE63986B1 (en) 1995-06-28

Similar Documents

Publication Publication Date Title
ATE204750T1 (de) Pharmazeutische zubereitung zur anwendung in den atemwegen
ZA9010452B (en) Pharmaceutical preparation for oral administration in fluid form
GR3035045T3 (en) Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof.
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
IL83059A0 (en) Stable cephalosporin derivatives,process for the preparation thereof and a gelatine capsule composition containing the same
ATE119766T1 (de) Zubereitung für den magen.
IL89691A0 (en) Pharmaceutical compositions containing bis(3,4-dihydro-2h-1-benzopyran)derivatives for lowering blood pressure,certain such novel compounds and their preparation
IT1235532B (it) Composti carbossiammidici, procedimenti per la preparazione dei medesimi e composizione farmaceutica contenente i medesimi
EP0141300A3 (en) An occulusion compound of 2-nitroxymethyl-6-chloropyridine with beta-cyclodextrin and process for preparation thereof
EP0357793A4 (en) Suspended-release preparation prepared by using alginic acid
IL103516A0 (en) Cytotoxic bicyclo(7,3,1)tridec-4-ene-2,6-diyne compounds,process for the preparation thereof and pharmaceutical compositions containing them
IL95158A0 (en) Pharmaceutical composition for oral administration containing n-acetyl-cysteine
AU638083B2 (en) Swallowable dosage units comprising colloidal bismuth subcitrate
HUT49808A (en) Process for producing retarde pharmaceutical compositions containing aselastine
GR890100833A (en) Process for the preparation of a compound with gastric inhibitopy effect
NZ234211A (en) Recompressed sustained release oral pharmaceutical composition containing water sensitive pharmaceutical agents, cellulose polymer and a lubricant
CS240991A3 (en) Solid forms for oral administration, said forms containing iphosphamide as active component
DE69017839D1 (de) NMDA-blockierende Verbindungen, pharmazeutische Präparate, deren Herstellung und Verwendung.
AU660296B2 (en) Pharmaceutical compositions containing functionalized vinylazoles, use of these vinylazoles for producing medicaments, these vinylazoles themselves and process for producing the same
IL113167A0 (en) A sustained release pharmaceutical excipient containing a heteropolysaccharide gum and methods for the preparation thereof
IL113816A0 (en) Pharmaceutical compositions containing desogestrel their preparation and use
FR2614890B1 (fr) Compose resultant du couplage d'une molecule a structure chimiosensibilisante et d'une molecule a structure cytotoxique, procede de preparation, application a titre de medicament et compositions pharmaceutiques le contenant
ZA947401B (en) Use of partially methylated beta-cyclodextrins as absorption promoters in the preparation of pharmaceutical compositions for the transcutaneous administration of active principles
IL102000A0 (en) Elsamicin a derivatives modified at the 2"-amino groups,their preparation and pharmaceutical compositions containing them
SE8106498L (sv) Kvaternera salter av n,n3-di(beta-brompropionyl)-n1,n2-dispirotripiperazinium, forfarande for framstellning av desamma och lekemedelspreparat innehallande desamma